Presentation is loading. Please wait.

Presentation is loading. Please wait.

Enrollment, outcomes, and pharmacokinetics.

Published byRadomír Urban Modified over 4 years ago

Similar presentations

Presentation on theme: "Enrollment, outcomes, and pharmacokinetics."— Presentation transcript:

1 Enrollment, outcomes, and pharmacokinetics.
Enrollment, outcomes, and pharmacokinetics. A: A total of 329 patients with type 2 diabetes underwent physical and biochemical screening; 231 were found to be ineligible according to entry criteria. Ninety-eight patients were randomly assigned to receive either gevokizumab or placebo. In the gevokizumab group, one patient was withdrawn after <1 week. A total of 98 patients completed the 13-week treatment and evaluation of study end points. B, C, and D: Plasma concentrations following a single intravenous (IV) (n = 55) (B), subcutaneous (SC) (n = 16) (C), or multiple subcutaneous (n = 10) (D) doses of gevokizumab. (A high-quality color representation of this figure is available in the online issue.)‏ Claudia Cavelti-Weder et al. Dia Care 2012;35: ©2012 by American Diabetes Association

Download ppt "Enrollment, outcomes, and pharmacokinetics."

Similar presentations

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Featured Article: Claudia Cavelti-Weder, M.D., Andrea Babians-Brunner, M.D.,

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Featured Article: Claudia Cavelti-Weder, M.D., Andrea Babians-Brunner, M.D.,
Protocol for the management of adult patients with DKA

Protocol for the management of adult patients with DKA
Protocol for management of adult patients with DKA or HHS

Protocol for management of adult patients with DKA or HHS
Protocol for the management of adult patients with HHS

Protocol for the management of adult patients with HHS
Volume 24, Issue 5, Pages (May 2016)

Volume 24, Issue 5, Pages (May 2016)
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.

Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.
Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.
Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.
The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.
Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.
A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Schematic representation of an MR analysis.

Schematic representation of an MR analysis.
Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.
Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Similar presentations

Ads by Google